Welcome to our dedicated page for Telomir Pharmaceuticals news (Ticker: TELO), a resource for investors and traders seeking the latest updates and insights on Telomir Pharmaceuticals stock.
Telomir Pharmaceuticals, Inc. (symbol: TELO) is a pre-clinical-stage pharmaceutical company dedicated to the development and commercialization of innovative therapies for age-related conditions. The company’s flagship product, TELOMIR-1, is a novel small molecule designed to function as an oral in situ therapeutic treatment for human stem cells. The primary focus of TELOMIR-1 is to elongate telomere caps on human stem cells, which has shown promise in reversing age-related inflammatory conditions.
In collaboration with Frontage Laboratories, Telomir Pharmaceuticals has presented significant pre-clinical data demonstrating TELOMIR-1's potential benefits. These studies highlight the molecule’s ability to extend DNA telomeres, paving the way for advancements in treating and possibly reversing the effects of aging at the cellular level.
The company leverages computer-aided pre-clinical testing to refine and optimize TELOMIR-1, ensuring its efficacy and safety. This rigorous testing process underlines Telomir Pharmaceuticals' commitment to bringing groundbreaking, science-backed treatments to market.
Telomir Pharmaceuticals maintains a robust pipeline of projects aimed at addressing various other age-related conditions, with ongoing research and collaboration efforts. The strategic partnerships and continued investment in innovative technologies mark Telomir Pharmaceuticals as a key player in the biopharmaceutical industry.
Telomir Pharmaceuticals (NASDAQ:TELO) has secured $1 million in equity funding through The Starwood Trust at $7 per share, representing a 20% premium to the closing price. The deal involves restricted common stock with no warrants and follows a previously secured $5 million non-dilutive credit line.
The company recently reported breakthrough preclinical results for Telomir-1, demonstrating age-reversal benefits and potential Type 2 diabetes treatment capabilities. The compound showed significant reductions in fasting plasma glucose levels and improved glucose homeostasis. Telomir-1 targets root causes of aging and disease, including oxidative stress, chronic inflammation, and telomere shortening.
The company is expanding research across multiple conditions, including Progeria, Alzheimer's Disease, Cancer, Wilson Disease, and Osteoarthritis.
Telomir Pharmaceuticals (NASDAQ:TELO) announced groundbreaking preclinical results showing its molecule Telomir-1 effectively reversed key Type 2 diabetes parameters in zebrafish models. The study demonstrated significant reductions in fasting plasma glucose levels, improved glucose homeostasis, and reversed insulin resistance to near pre-diabetic levels, supported by improved HOMA-IR values. The research, conducted with Pentagrit, tested two forms of Telomir-1 at three doses, showing dose-dependent efficacy in normalizing blood glucose and reducing insulin levels. The molecule's mechanism focuses on normalizing iron metabolism to reduce oxidative stress and improve insulin sensitivity. The company is expanding research into progeria, Alzheimer's, osteoarthritis, and cancer models.
Telomir Pharmaceuticals (NASDAQ:TELO) announced groundbreaking preclinical results for Telomir-1, demonstrating significant age-reversal effects in aging model organisms. The study, conducted with Nagi Biosciences SA using advanced microfluidic technology, showed enhanced mobility in older organisms, reduced biological aging, and increased lifespan in treated populations.
The research utilized Caenorhabditis elegans as a model organism, testing two forms of Telomir-1 at different concentrations. The company is expanding research to investigate Telomir-1's potential in treating progeria, collaborating with the Progeria Foundation to study effects on human progeria cell lines.
Telomir Pharmaceuticals (NASDAQ:TELO) announces that its Special Advisor, Dr. Michael F. Roizen, will be featured on Health Uncensored with Dr. Drew on Fox Business Network on Sunday, September 29, 2024, at 5:30 PM EST. Dr. Roizen will discuss the science of longevity and the importance of telomeres in the aging process, focusing on Telomir-1, the company's novel small molecule designed to elongate telomere caps.
The segment will explore how Telomir-1 could potentially transform the treatment of age-related conditions and extend healthy human and canine lifespans. Dr. Roizen, a leading wellness and longevity specialist, will explain the critical role of telomeres in aging and how Telomir-1 offers an opportunity to support stem cell health and target aging mechanisms.
Erez Aminov, Chairman and CEO of Telomir, highlighted the company's ongoing research projects aimed at expediting regulatory applications for Telomir-1 in both veterinary and human applications.
Telomir Pharmaceuticals (NASDAQ:TELO) has appointed Dr. Itzchak Angel as Chief Scientific Advisor to expedite the development of Telomir-1, a novel small molecule designed to lengthen telomeres. Dr. Angel, former Head of Pharmacology at Synthelabo (now Sanofi-Aventis), brings over 40 years of expertise in drug development. Telomir is pursuing both Investigational New Drug (IND) and Investigational New Animal Drug (INAD) applications for Telomir-1.
The company is exploring Telomir-1's potential for treating rare aging-related diseases like progeria, which could qualify for orphan drug designation. Dr. Angel will focus on unveiling the molecular mechanisms of Telomir-1, including its effects on ion-chelation, cytokine modification, and intracellular pathways. This appointment aims to accelerate Telomir's progress in longevity science and the treatment of age-related conditions in both humans and animals.
Telomir Pharmaceuticals (NASDAQ:TELO) has been featured in a local ABC exclusive highlighting promising age reversal outcomes in two senior dogs using their novel small molecule, Telomir-1. The compassionate use program, observed by Dr. Michael Roizen, showed remarkable improvements in the dogs' health and vitality. Zeus, a 12-year-old German Shepherd, experienced complete remission of terminal cancer, while Benson, a 12-year-old Newfoundland with severe arthritis, regained mobility.
Erez Aminov, Telomir's new Chairman CEO, emphasized the company's commitment to advancing Telomir-1's research and accelerating its path to market. Dr. Roizen expressed excitement about Telomir-1's potential to promote cell regeneration and reverse aspects of aging by lengthening telomeres. The company aims to progress towards human trials for specific indications.
Telomir Pharmaceuticals (Nasdaq: TELO) announced the passing of its Chairman and CEO, Dr. Christopher Chapman. The company's Board of Directors has appointed Erez Aminov as the new CEO and Chairman. Aminov is currently the CEO and Chairman of MIRA Pharmaceuticals (Nasdaq: MIRA).
In addition, Telomir announced changes to its Board of Directors. Three directors have voluntarily resigned, and three new directors have been appointed: Dr. Matthew P. Del Giudice, Mr. Ned MacPherson, and Matthew Pratt Whalen, CPA. Dr. Craig Eagle and Michael Jerman will remain on the board.
Telomir Pharmaceuticals is a pre-clinical-stage company focused on developing Telomir-1, a drug candidate aimed at promoting longevity in humans and dogs through the treatment of age-related conditions.
Telomir Pharmaceuticals (Nasdaq: TELO), a pre-clinical-stage pharmaceutical company, has been added to the Russell 3000 and Russell Microcap Indexes as of July 1, 2024.
This inclusion follows the annual Russell indexes reconstitution, which ranks the 4,000 largest US stocks by market capitalization. Membership in these indexes signifies automatic inclusion in either the Russell 1000 or Russell 2000 indexes, impacting index funds and active investment strategies.
FTSE Russell manages these indexes, which benchmark approximately $10.5 trillion in assets. Telomir's CEO, Dr. Chris Chapman, highlighted this milestone as evidence of the company's progress since its IPO in February and its commitment to advancing Telomir-1, a potential treatment for age-related conditions.
Telomir Pharmaceuticals (Nasdaq: TELO), a pre-clinical-stage pharmaceutical company, announced the participation of its scientific advisor, Dr. Adam Kaplin, in the Drug Information Association (DIA) 2024 Global Annual Meeting on June 17, 2024. The event, being the largest global gathering for professionals in pharmaceuticals, biotechnology, and medical devices, will feature Dr. Kaplin in a panel discussion on generative AI in clinical trials. He will discuss how AI-powered data modeling can significantly reduce time and cost in therapeutic studies while maintaining high patient safety standards. This approach has the potential to expedite drug dosing, trial performance, and patient safety by up to 90%.
Telomir Pharmaceuticals (Nasdaq: TELO) announced significant milestones for its lead product candidate, Telomir-1. The Company began a pivotal study on May 28, 2024, to evaluate the safety and efficacy of Telomir-1 in geriatric laboratory Beagle dogs over 63 days. The initial dosing was well-tolerated by all animals, aiming to treat age-related conditions like gait weakness and joint damage. Additionally, Telomir is treating a 12-year-old German Shepherd named Zeus with Telomir-1, gathering real-world data for future research and regulatory efforts. These studies are key steps towards developing treatments for both veterinary and human age-related diseases.
FAQ
What is the current stock price of Telomir Pharmaceuticals (TELO)?
What is the market cap of Telomir Pharmaceuticals (TELO)?
What does Telomir Pharmaceuticals, Inc. specialize in?
What is TELOMIR-1?
What are telomeres?
Who is Telomir Pharmaceuticals partnered with?
What potential does TELOMIR-1 hold?
What stage is Telomir Pharmaceuticals currently in?
How does Telomir Pharmaceuticals ensure the safety of their products?
What are the future plans for Telomir Pharmaceuticals?
How can I contact Telomir Pharmaceuticals?
Where can I find more information about Telomir Pharmaceuticals?
